UTHR: Expanding into pulmonary fibrosis and COPD, targeting multi-billion revenue growth with new therapies
A major strategic shift is underway, expanding from orphan pulmonary hypertension to large pulmonary fibrosis and COPD markets, with multiple new products and formulations in late-stage development. Revenue is projected to grow significantly, supported by robust clinical data, IP protection, and ag…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.